Program
plozasiran
Also written as “Plozasiran Injection”, “ARO-APOC3” and “Plozasiran”.
Its studies are mostly in Hypertriglyceridemia · Dyslipidemias · Hyperlipoproteinemia Type I, led by 2 companies.
Drug pagePlozasiran: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arrowhead Pharmaceuticalsits history only | 102 open or running | phase 3since Oct 11, 2021 | Dec 19, 2018 | Jul 2028phase 3 · NCT06822790 |
| Visirna Therapeutics HK | 20 open or running | phase 3since May 31, 2023 | Feb 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Visirna Therapeutics HK only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 14, 2023First study: phase 1 study in Healthy Adult VolunteersFirst studyNCT05757596 · 24 enrolled · China
- May 31, 2023Phase 3 study in Familial hyperchylomicronemia syndromeNCT05902598 · 37 enrolled · China
- Feb 29, 2024Named plozasiranINNProposed as its International Nonproprietary Name in WHO's List 130
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Visirna Therapeutics HK leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05902598Familial hyperchylomicronemia syndrome · China | 3 | Completed | Nov 26, 2024 | 37 |
| NCT05757596Healthy Adult Volunteers · China | 1 | Completed | Sep 25, 2023 | 24 |
How it is read
Names in the registry
- “Plozasiran Injection”, 4 entries
- “ARO-APOC3”, 4 entries
- “Plozasiran”, 3 entries
- “VSA001 injection”, 1 entry
Codes read as this program: VSA001.
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 7 studies
- Dyslipidemias, 2 studies
- Hyperlipoproteinemia Type I, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.